MYRICX

Pharmaceutical and biotechnological preparations; pharmaceutical and biotechnological preparations for the diagnosis and treatment of human diseases; pharmaceutical and biotechnological preparations for the diagnosis and treatment of proliferative human diseases; pharmaceutical and biotechnological preparations for the diagnosis and treatment of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging; antibody drug conjugates (ADCs); antibody drug conjugates (ADCs) for the diagnosis and treatment of human diseases; antibody drug conjugates (ADCs) for the diagnosis and treatment of proliferative human diseases; antibody drug conjugates (ADCs) for the diagnosis and treatment of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging; N-myristoyltransferases (NMT) inhibitors; N-myristoyltransferases (NMT) inhibitors for the diagnosis and treatment of human diseases; N-myristoyltransferases (NMT) inhibitors for the diagnosis and treatment of proliferative human diseases; N-myristoyltransferases (NMT) inhibitors for the diagnosis and treatment of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging.

Scientific and biomedical research; scientific and biomedical research in the field of human diseases; scientific and biomedical research in the field of proliferative human diseases; scientific and biomedical research in the field of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging; development, testing and commercialisation of pharmaceuticals and biotechnological preparations (term considered too vague by the International Bureau pursuant to Rule 13 (2) (b) of the Regulations); development, testing and commercialisation of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of human diseases (term considered too vague by the International Bureau pursuant to Rule 13 (2) (b) of the Regulations); development, testing and commercialisation of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of proliferative human diseases (term considered too vague by the International Bureau pursuant to Rule 13 (2) (b) of the Regulations); development, testing and commercialisation of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging (term considered too vague by the International Bureau pursuant to Rule 13 (2) (b) of the Regulations); development, testing and commercialisation of antibody drug conjugates (ADCs) and N-myristoyltransferases (NMT) inhibitors (term considered too vague by the International Bureau pursuant to Rule 13 (2) (b) of the Regulations); consultancy, advisory and information services relating to the aforesaid services.